Hepatology. 2007 Jan;45(1):80- 7.

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH,
Wahed AS.

University of Michigan, Ann Arbor, MI.

Hepatic steatosis is common in chronic hepatitis C and has been linked to
concurrent obesity, insulin resistance, diabetes, disease severity, and poor
response to therapy. Racial differences in rates of obesity and diabetes may
contribute to racial differences in hepatic steatosis and treatment
response. The aim of the present study was to compare hepatic steatosis and
its associations between African American (AA) and Caucasian American (CA)
patients with chronic hepatitis C, genotype 1, participating in a
prospective study of peginterferon and ribavirin therapy. Liver biopsy
results were available from 194 AA patients and 205 CA patients. The 2
groups were compared for anthropometric, clinical, and biochemical features
and insulin resistance estimated by the homeostasis model assessment index
(HOMA-IR). Sixty-one percent of the AA patients and 65% of the CA patients
had hepatic steatosis (P = 0.38). In univariable analysis, steatosis was
associated with HOMA-IR, body mass index, waist circumference, serum
triglycerides, aminotransferase level, and histological scores for
inflammation and fibrosis. After adjusting for these features, AA patients
had a lower risk of steatosis than did CA patients (OR 0.54, 95% CI
0.32-0.91, P = 0.02). Insulin resistance but not steatosis was associated
with a lower rate of sustained virological response when adjusted for known
factors that predict response (relative risk 0.87, 95% CI 0.77-0.99, P =
0.028). Conclusion: After adjusting for the higher prevalence of features
associated with hepatic steatosis, AA patients had a lower prevalence of
hepatic steatosis than did CA patients with chronic hepatitis C, genotype 1.
Insulin resistance but not steatosis was independently associated with lower
sustained virological response. (HEPATOLOGY 2006;45:80-87. ).

PMID: 17187406 [PubMed - in process]


Sandra Tara Balduf (Ane)

Support for patients and educational materials

regarding all forms of liver disease.

http://frontline-hepatitis-awareness.com

509-888-0587






[Non-text portions of this message have been removed]